U.S. market Closed. Opens in 4 hours 1 minute

BIAF | bioAffinity Technologies, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.3610 - 1.3900
52 Week Range 1.2500 - 3.62
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 15,673
Average Volume 125,965
Shares Outstanding 13,490,273
Market Cap 18,616,577
Sector Healthcare
Industry Medical - Diagnostics & Research
IPO Date 2022-09-01
Valuation
Profitability
Growth
Health
P/E Ratio -1.52
Forward P/E Ratio N/A
EPS -0.91
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 75
Country USA
Website BIAF
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
BIAF's peers: PRPO, STRR, TTOO, WLDSW, IDXG, INBS, SQL, BIOC, GENE, HTGM, GTH, PMD, BIAFW, KNW
*Chart delayed
Analyzing fundamentals for BIAF we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see BIAF Fundamentals page.

Watching at BIAF technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on BIAF Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙